This document relates to methods and materials involved in assessing and treating mammals (e.g., humans) with non-Hodgkins lymphoma (e.g., diffuse large B-cell lymphoma). For example, this document provides materials and methods for determining if a human (e.g., a human having non-Hodgkins lymphoma) has a MAN1A2 variant (e.g., a SNP) that decreases response to treatment (e.g., rituximab treatment). For example, this document provides materials and methods for using one or more alternative non-Hodgkins lymphoma treatments to treat a mammal having a MAN1A2 variant.
